Diffusing Capacity Of The Lungs For Carbon Monoxide


Pulmonary function tests are performed to assess lung function. Spirometry is the most common and widely used lung function test, followed by diffusing capacity of the lungs for carbon monoxide (DLCO). It is also known as the transfer factor.[1] DLCO is a measurement to assess the lungs' ability to transfer gas from inspired air to the bloodstream.[2] Carbon monoxide (CO) has a high affinity for hemoglobin, and it follows the same pathway as that of oxygen to finally bind with hemoglobin. Inhaled CO is used for this test due to its high affinity for hemoglobin (200 to 250 times that of oxygen). Among other potential gases for evaluating diffusing capacity, oxygen is not preferred since its uptake is limited by cardiac uptake and total body consumption. 

In brief, during a ten-second breath-hold, DLCO measures uptake of CO per unit time per mm of driving pressure of CO (cc of CO/sec/mm of Hg).

The respiratory membrane forms the diffusing barrier. It separates air within the alveoli from blood flowing in the pulmonary capillaries. It consists of the following layers: 

  • Alveolar epithelium
  • Interstitium
  • Capillary endothelium

According to Fick's equation for the diffusion of gas[3]:

Vg=[k*(A)(ΔP)] / T

  • V = volume of gas transferred per unit time
  • K = diffusion coefficient of the gas
  • A = surface area for gas exchange
  • ΔP = partial pressure difference of gas
  • T = membrane thickness

from this law, factors that influence the movement of gas molecules across the capillary membrane are the surface area of the membrane (A), the thickness of the membrane (T), driving pressure/pressure gradient across the capillary membrane (ΔP).[4]

As a consequence, the diffusion of gas across the alveolar membrane increases with:

  • Increased surface area of the membrane (A) 
  • Increased alveolar pressure gradient(ΔP) 
  • Increased solubility of the gas
  • Decreased membrane thickness (T)

On the other hand, the diffusion of gas across the alveolar membrane decreases with:

  • Decreased surface area of the membrane (A) 
  • Decreased alveolar pressure gradient(ΔP) 
  • Decreased solubility of the gas
  • Increased membrane thickness (T)


DLCO is measured using the following techniques[1]:

  • Single breath method
  • Intrabreath method
  • Rebreathing technique

In the single breath method, the patients are initially asked to take normal resting breaths initially; this is followed by full exhalation up to residual volume (RV). The patient is then asked to rapidly inhale the test gas up to vital capacity (VC). The test gas contains: 

  • 0.3% CO
  • 0.3% tracer gas (helium, methane, or neon)
  • 21% oxygen
  • Balance nitrogen

The patient is then asked to hold his breath for 10 seconds at total lung capacity (TLC). Subsequently, the patient exhales out completely, and exhaled gas is collected for analysis after excluding the initial amount of gas from dead space. The collected gas is analyzed for CO and tracer concentrations. Total lung volume, initial and final CO concentration, and breath-holding time are used to calculate DLCO. The recommended timing method used is the Jones and Meade method, which measures breath holding time at thirty percent of inspiratory time up to half of the sampling time. Usually, an average of two or more attempts is considered for DLCO calculation in the single breath-holding technique.

Another method to calculate DLCO is the intrabreath method, which is calculated during exhalation. The gas that exits during the initial phase of exhalation has less time to diffuse from alveoli to capillaries and will have a higher concentration of CO compared to the gas during later stages of exhalation. The difference between various exhaled gas samples can be used to calculate DLCO.

The rebreathing technique is less frequently used, usually during exercise studies. However, a study carried out by Liu et al. showed the rebreathing technique to be more consistent with respiratory system physiology and could be a better test in measuring diffusing capacity than the intrabreath method.[5] Another study conducted by Suzuki et al. showed that the intrabreath method is a reliable alternative to the single breath method to measure diffusion capacity.[6]


DLCO is indicated in the evaluation of parenchymal and non-parenchymal lung diseases in conjunction with spirometry. The severity of obstructive and restrictive lung diseases, pulmonary vascular disease, and preoperative risk can be assessed using DLCO.[7]

Normal and Critical Findings

Severity and classification of DLCO reduction[8]:

  • Normal DLCO: >75% of predicted, up to 140%
  • Mild: 60% to LLN (lower limit of normal)
  • Moderate: 40% to 60%
  • Severe: <40%

Interfering Factors

DLCO adjustment:

  • Effect of hemoglobin on DLCO: Anemia can reduce DLCO. Hence DLCO is adjusted for hemoglobin values. Various calculators are available to calculate DLCO adjusted for hemoglobin.
  • DLCO may need to be adjusted for several other factors like carboxyhemoglobin, FiO.


DLCO contraindications:

Measurements of pulmonary diffusing capacity are contraindicated in cases of chest and abdominal pain, oral or facial pain, dementia, or stress incontinence.[9]

The usual recommendation is to postpone pulmonary function testing by a month in cases of acute coronary syndrome or myocardial infarction. PFT is also contraindicated in patients with pneumothorax, ascending aortic aneurysm, pulmonary embolism, severe hypertension, hemoptysis, and major surgeries like thoracic/abdominal /brain/eye/ear/otolaryngological surgery.[8]

Patient Safety and Education

Role of Registered Respiratory Therapist 

An optimal test performance requires optimal patient performance. It is important to coach patients to adapt instructions in different ways, including exaggerated body language. Registered respiratory therapists and other laboratory personnel play an important role in achieving acceptable and repeatable trials.[10]

Clinical Significance

Interpretation of DLCO

  • DLCO= Va X Kco

Va: number of contributing alveolar units measured by tracer gas (helium)

Kco: CO transfer coefficient, usually written as  DLCO/Va, which indicates the efficiency of CO transfer by alveoli.

A decrease in DLCO will be due to a decrease in Va, Kco, or both.

Low DLCO and Low KCO: seen in COPD with emphysema due to alveolar destruction (usually normal in chronic bronchitis) with an obstructive pattern on PFT.

Smoking can also cause a decrease in DLCO.[11] 

DLCO and KCo are also reduced in interstitial lung diseases, pulmonary fibrosis due to the thickening of the alveolar-capillary membrane with a restrictive pattern on PFT.[7]

A normal DLCO with a restrictive pattern on PFT suggests neuromuscular or chest wall disorder. 

In dyspnea cases of unknown etiology, the pattern of normal spirometry with low DLCO increases the likelihood of pulmonary vascular disease. However, this pattern may also present in other disorders, e.g., mild ILD.[1]

High DLCO is seen in conditions like obesity, asthma, which are characterized by large lung volumes.[12] KCo may be raised in conditions involving profuse pulmonary hemorrhage (e.g., Goodpasture syndrome, systemic lupus erythematosus, granulomatosis with polyangiitis). This is due to the uptake of CO by free RBCs lining the alveoli. When hemoglobin is broken down, KCO levels drop back to normal. 

(Click Image to Enlarge)
Single Breath DLCO
Single Breath DLCO
Contributed by Pranav Modi, MBBS
Article Details

Article Author

Pranav Modi

Article Editor:

Marco Cascella


3/13/2023 3:49:52 PM



Enright Md P. Office-based DLCO tests help pulmonologists to make important clinical decisions. Respiratory investigation. 2016 Sep:54(5):305-11. doi: 10.1016/j.resinv.2016.03.006. Epub 2016 May 2     [PubMed PMID: 27566377]


. "2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung." Brian L. Graham, Vito Brusasco, Felip Burgos, Brendan G. Cooper, Robert Jensen, Adrian Kendrick, Neil R. MacIntyre, Bruce R. Thompson and Jack Wanger. Eur Respir J 2017; 49: 1600016. The European respiratory journal. 2018 Nov:52(5):. pii: 1650016. doi: 10.1183/13993003.50016-2016. Epub 2018 Nov 22     [PubMed PMID: 30467174]


Chandan G, Cascella M. Gas Laws and Clinical Application. StatPearls. 2022 Jan:():     [PubMed PMID: 31536199]


Powers KA, Dhamoon AS. Physiology, Pulmonary Ventilation and Perfusion. StatPearls. 2023 Jan:():     [PubMed PMID: 30969729]


Liu QX, Zheng JP, Xie YQ, Guan WJ, Jiang CY, An JY, Yu XX, Liu WT, Gao Y. [Single-breath and rebreathing methods for measurement of pulmonary diffusing function: a comparative study]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases. 2013 Jul:36(7):510-5     [PubMed PMID: 24262087]


Suzuki T, Yoshimi K, Ueki J, Fukuchi Y. [Measurement of diffusing capacity by the intrabreath method]. Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society. 2005 Jun:43(6):347-53     [PubMed PMID: 15997784]


Heckman EJ, O'Connor GT. Pulmonary function tests for diagnosing lung disease. JAMA. 2015 Jun 9:313(22):2278-9. doi: 10.1001/jama.2015.4466. Epub     [PubMed PMID: 26057290]


Ponce MC, Sankari A, Sharma S. Pulmonary Function Tests. StatPearls. 2022 Jan:():     [PubMed PMID: 29493964]


Zavorsky GS, Blood AB, Power GG, Longo LD, Artal R, Vlastos EJ. CO and NO pulmonary diffusing capacity during pregnancy: Safety and diagnostic potential. Respiratory physiology & neurobiology. 2010 Mar 31:170(3):215-25. doi: 10.1016/j.resp.2010.02.001. Epub 2010 Feb 10     [PubMed PMID: 20149901]


Cheung HJ, Cheung L. Coaching patients during pulmonary function testing: A practical guide. Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR. 2015 Summer:51(3):65-8     [PubMed PMID: 26283871]


Sansores RH, Pare PD, Abboud RT. Acute effect of cigarette smoking on the carbon monoxide diffusing capacity of the lung. The American review of respiratory disease. 1992 Oct:146(4):951-8     [PubMed PMID: 1416424]


Saydain G, Beck KC, Decker PA, Cowl CT, Scanlon PD. Clinical significance of elevated diffusing capacity. Chest. 2004 Feb:125(2):446-52     [PubMed PMID: 14769723]